Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syntara Limited ( (AU:SNT) ) has shared an announcement.
Syntara Limited reports a year of significant clinical progress, led by compelling final Phase 2a data for its lead drug amsulostat in myelofibrosis, which showed durable responses and a favourable tolerability profile and has driven growing commercial interest. The company has broadened the amsulostat opportunity through additional myelodysplastic syndrome studies and is finalising an FDA-aligned Phase 2b design in myelofibrosis, setting up a pivotal first half of 2026 for key regulatory, investor and partnership discussions. In parallel, Syntara has rapidly advanced its next-generation skin scarring candidate SNT-9465 following earlier tolerability issues with a prior compound, and has crafted an innovative, efficiency-focused clinical pathway aimed at achieving proof-of-concept and clarifying commercial value next year. The pipeline is further supported by an upcoming Phase 2 data readout for SNT-4728 in isolated REM sleep behaviour disorder, which will assess symptomatic benefit and potential impact on progression toward Parkinson’s or Lewy Body dementia, with multiple 2026 readouts described as potentially transformational for patients and shareholders.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies in hematology, dermatology and neurodegenerative disease. Its lead asset, amsulostat, targets myelofibrosis and myelodysplastic syndromes, while additional pipeline programs include a next‑generation skin scarring candidate, SNT-9465, and SNT-4728 for isolated REM sleep behaviour disorder, with the company leveraging an in-house discovery platform to advance multiple indications with high unmet medical need.
Average Trading Volume: 2,321,377
Technical Sentiment Signal: Sell
Current Market Cap: A$48.97M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.